Combining Genetic Variants to Improve Risk Prediction for NAFLD and Its Progression to Cirrhosis: A Proof of Concept Study

Table 1

Epidemiologic and clinical data and frequency of the PNPLA3 rs738409 G, TM6SF2 rs58542926 T, KLF6 rs3750861 T, SOD2 rs4880 T, and LPIN1 rs13412852 T alleles in the study population, divided according to subgroups.

	All	Healthy Subjects	Noncirrhotic NAFLD	NASH cirrhosis
	290	90	93	107
Age (years)	54.4 (15.1)	43.1 (11.9)	51.6 (13.2)	66.2 (9.8)
Sex (male)	53.5%	46.6%	60.2%	53.3%
BMI (Kg/m^2)	28.8 (5.3)	25.2 (4.6)	29.5 (4.1)	31.2 (5.2)
T2DM	41.6%	7%	45.2%	66.4%
PNPLA3 G allele frequency	0.46	0.24	0.48	0.61
TM6SF2 T allele frequency	0.11	0.06	0.11	0.14
KLF6 T allele frequency	0.08	0.06	0.07	0.12
SOD2 T allele frequency	0.5	0.48	0.53	0.49
LPIN1 T allele frequency	0.32	0.35	0.32	0.31

Data are shown as mean (standard deviation) or percentages. < 0.05 and < 0.001 versus healthy subjects; < 0.01 and < 0.001 versus noncirrhotic NAFLD; NAFLD: nonalcoholic fatty liver disease; NASH: nonalcoholic steatohepatitis; BMI: body mass index; T2DM: type 2 diabetes mellitus; PNPLA3: patatin-like phospholipase domain containing protein 3; TM6SF2: transmembrane 6 superfamily member 2; KLF6: Kruppel-like factor 6; SOD2: superoxide dismutase 2; LPIN1: lipin 1.